StockData
Cognition Therapeutics Inc logo

Cognition Therapeutics Inc (CGTX) stock

CGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.63−0.01 (-1.39%)

Close on Nov 17, 2026Market cap $59.90MP/E –Yield –

Cognition Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Cognition Therapeutics's ebitda for the twelve months ending Dec 31, 2025 was -$47.76M. For fiscal 2025 it was -$47.76M. The highest annual figure on record is -$17.31M in fiscal 2020.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$47.76M–
FY2024Dec 31, 2024-$53.86M–
FY2023Dec 31, 2023-$50.63M–
FY2022Dec 31, 2022-$43.47M–
FY2021Dec 31, 2021-$28.51M–
FY2020Dec 31, 2020-$17.31M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$13.66M–
Q3 FY2025Sep 30, 2025-$6.36M–
Q4 FY2024Dec 31, 2024-$10.70M–
Q3 FY2024Sep 30, 2024-$14.44M–
Q2 FY2024Jun 30, 2024-$14.65M–
Q1 FY2024Mar 31, 2024-$14.08M–
Q4 FY2023Dec 31, 2023-$15.16M–
Q3 FY2023Sep 30, 2023-$14.72M–
Q2 FY2023Jun 30, 2023-$11.79M–
Q1 FY2023Mar 31, 2023-$8.95M–
Q4 FY2022Dec 31, 2022-$9.28M–
Q3 FY2022Sep 30, 2022-$12.60M–
Q2 FY2022Jun 30, 2022-$12.19M–
Q1 FY2022Mar 31, 2022-$9.40M–
Q4 FY2021Dec 31, 2021-$11.79M–
Q3 FY2021Sep 30, 2021-$5.20M–
Q2 FY2021Jun 30, 2021-$5.96M–
Q1 FY2021Mar 31, 2021-$5.56M–
Q4 FY2020Dec 31, 2020-$4.10M–

More Cognition Therapeutics figures

See a number that looks wrong?